Lucy McKinna
Lucy graduated as a vet from the University of Melbourne in 2007 and has worked in companion animal practice in the UK and the Middle East ever since. Passionate about animals, the environment and corporate responsibility, 5 years ago she had the idea to make a vegan dog food with an ingredient list and a nutritional analysis that made her feel like she was doing a great thing for her dog, as well as the planet, launching the flagship product in the range, Noochy Poochy Adult in June last year.
David Whitehouse
Julia Pike
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Dr. Sadegh Riazi
Dr. Sadegh Riazi is a technology enthusiast, currently co-founder and CEO of CipherMode Labs. He received his Ph.D. in secure computation from UC San Diego where he was awarded the best Ph.D. thesis award. Sadegh founded Project HEAX at Microsoft Research (a new computing platform for Homomorphic Encryption). Prior to that, he studied Electrical Engineering and designed a new system for Brain-Computer Interfaces. Sadegh is a fellow of the Institute for Global Entrepreneur and has received multiple prestigious awards including Richard Newton Young Fellow Award, Jacobs Graduate Student Award, and Silver Medal in International Student Olympiad.
Dr. Sadegh Riazi
Dr. Sadegh Riazi is a technology enthusiast, currently co-founder and CEO of CipherMode Labs. He received his Ph.D. in secure computation from UC San Diego where he was awarded the best Ph.D. thesis award. Sadegh founded Project HEAX at Microsoft Research (a new computing platform for Homomorphic Encryption). Prior to that, he studied Electrical Engineering and designed a new system for Brain-Computer Interfaces. Sadegh is a fellow of the Institute for Global Entrepreneur and has received multiple prestigious awards including Richard Newton Young Fellow Award, Jacobs Graduate Student Award, and Silver Medal in International Student Olympiad.
Jessica McCreadie
Jess sits in the Health team, and her focus is engaging with, investing in and supporting Europe’s most promising health tech companies.
“The gap between health and life expectancy is widening and to improve quality of life in later years we need a more decentralised, preventative and personalised approach to healthcare.”
Prior to joining Octopus Ventures in June 2021, Jess led the health tech investing team at Legal & General supporting leading health innovations. She invested balance sheet capital into early-stage health tech businesses and supported scale up via board representation in her portfolio.
Earlier in her career Jess invested into and was a banker in a range of alternative asset classes including renewable energy, real estate, and Venture Capital Funds. Jess has a passion for sustainability and delivering social impact alongside economic value.
Outside of work Jess can be found enjoying London’s restaurants, cycling, running, trying out the newest fitness class on offer, or in the park running around with / after her dog.
Wolfgang Hackl
Translational oncology scientist and clinical cancer drug developer with over 20 years of experience directly contributing to pharmaceutical and scientific progress with leading companies worldwide. Proven record of achieving project and organizational objectives by building and leading high- performance teams, promoting cooperation, developing mitigation strategies, and analyzing results to ensure success. Dynamic senior leader with proactive approach to implementing efficient processes and improving staff capabilities. Effective communicator, using interpersonal abilities, active listening, and observational skills to promote genuine, productive discourse. Deeply passionate about cancer research, maintaining a strong vested interest in all assigned projects to drive quality and attain large-scale goals.
Demonstrated success in:
- Leading Femara global registration programs and teaming with colleagues on Aromasin registration.
- Contributing to Proof-of-Concept (POC) for multiple targeted investigational new drugs.
- Delivering expertise across all drug development stages: Discovery, pre-clinical research, POC, phase I to IV development.
- Translating complex concepts into clear, relevant ideas for multilateral understanding and alignment.
- Collaborating to create solutions, improving processes, and building strategies that enable success.
Demonstrated skills in:
Cancer Drug Development · Translational Clinical Oncology · NDA Filing · POC · Biomarker Development · Clinical Studies (Phase I-IV) · Medical Affairs · Wide-Ranging Subject Matter Expertise
- · Team Building · High Performance Leadership · Problem Solving